Clinic Software← All companies
SyzOnc
A new systems-level approach to cancer therapeutics
health AImedtechdigital healthoncology
StagePre-Seed
Raised$800,000
Founded2023
Employees4
LocationPhiladelphia, PA
Business modelB2B, potentially SaaS/enterprise platform (STEM3)
About
SyzOnc develops STEM3, an integrated platform for solid tumor drug discovery that maps tumor ecosystems using multi-modal tissue data and matrix biology, creates cancer type-specific AI/ML models, and identifies protein targets across cancer cells, immune cells, and tumor matrix. Based in Philadelphia, the company serves biotech and pharmaceutical companies seeking to develop therapeutics against solid tumors with poor survival rates.
Product
- Value proposition
- Integrated, systems-level oncology solution to map, model, and modulate the tumor ecosystem for improved drug discovery and patient outcomes
- Target customers
- Biotech and pharmaceutical companies, oncology researchers, potentially academic collaborators
Founders
- Anne Carpenter — Co-Founder, Chair of Scientific Advisory Board
- T. S. Karin Eisinger — Co-Founder, Chief Executive Officer
- Ashley M. Fuller — Co-Founder, Chief Scientific Officer
Categories
Products
STEM3 platform (System for Tumor Ecosystem Mapping/Modeling/Modulation)
Key features
Multi-modal tissue dataMatrix biologyPhenomicsProprietary cancer type-specific ecosystem modelsAI/ML models integrating ecosystem dataIn vivo model validationRapid genetic/compound phenotype comparisonTriple-threat protein target discovery (cancer cells, matrix, immune cells)
Technologies
AI/MLomics data integrationphenomicsin vivo validationtumor microenvironment modeling
Target conditions
Solid tumorscancer
Care settings
research labacademicbiotech/biopharma
Partnerships
QuBiGen - agreement with SyzOnc to apply AI-driven drug development to oncology targets
Investors
NIH
News
- SyzOnc - Systems Approach to Solid Tumors · 2025-11-24T00:00:00.000Z
- MSK Therapeutics Accelerator 2026 Cohort Launches with Kickoff... · 2026-06-19T00:00:00.000Z
- Qubigen Signs Agreement with SyzOnc to Apply AI-Driven Drug Development to Promising Oncology Targets · 2025-09-15T00:39:43.000Z
- Rethinking Solid Tumor Treatment - YouTube · 2025-06-16T00:00:00.000Z
- Anne Carpenter - Department of Biological Sciences · 2025-06-18T00:00:00.000Z
- Rethinking Solid Tumor Treatment-Philly Tech Connect by Philadelphia Tech Entrepreneurs · 2025-06-16T09:09:40.000Z
